A carregar...
Heterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation
We report the case of a 37‐year‐old male non‐small cell lung cancer patient with an active epidermal growth factor receptor (EGFR) mutation who received gefitinib as first‐line treatment. After 13.7 months, the patient experienced disease progression and was treated with platinum‐based doublet chemo...
Na minha lista:
| Publicado no: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons Australia, Ltd
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5217905/ https://ncbi.nlm.nih.gov/pubmed/27801981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12382 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|